Ofatumumab

證據等級: L5

預測適應症: 8 個

Ofatumumab: From Chronic Lymphocytic Leukemia to Follicular Lymphoma

One-Sentence Summary

Ofatumumab is a fully human anti-CD20 monoclonal antibody whose established use — per the literature captured in this evidence pack — is chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The TxGNN model's most clinically actionable new-indication prediction is Follicular Lymphoma (FL), a related CD20-positive B-cell lymphoma, supported by 15 clinical trials and 20 publications, including at least one completed randomized Phase 2 trial. Several other TxGNN-ranked predictions (molecular CLL/SLL subtypes, "metastatic neoplasm," malignant spiradenoma, Langerhans cell histiocytosis) carry little to no supporting evidence and are not considered viable candidates at this time.

Quick Overview

Item	Content
Original Indication	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) — reconstructed from literature within this evidence pack (e.g., PMID 22830942, PMID 20068404); not separately confirmed in the structured `drug.original_indications` field, which is empty
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.70% (rank #4073)
Evidence Level	L2
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available in the structured record (original_moa: Data Gap). Based on the literature retrieved in this evidence pack, ofatumumab is a second-generation, fully human IgG1κ anti-CD20 monoclonal antibody. It binds a distinct, membrane-proximal small-loop epitope on the CD20 antigen (distinguishing it from rituximab) and clears CD20-positive B cells primarily through complement-dependent cytotoxicity (CDC), with additional antibody-dependent cellular cytotoxicity (ADCC) and induction of apoptosis (PMID 20068404, PMID 23850806, PMID 32482755).

CLL/SLL and follicular lymphoma are both mature B-cell neoplasms that near-universally express CD20 on the malignant clone. Anti-CD20 antibodies (rituximab, ofatumumab, obinutuzumab) are already standard-of-care building blocks across this entire disease family — CLL/SLL, FL, diffuse large B-cell lymphoma, and other indolent B-NHL subtypes are frequently studied together in the same trials and reviews (PMID 28983798, PMID 29934061, PMID 25736010). Several trials in this evidence pack directly enrolled combined "indolent B-cell lymphoma" populations spanning both CLL/SLL and FL (e.g., NCT01239394, NCT01294579), reinforcing that the mechanistic rationale for extending ofatumumab into FL is not speculative — it mirrors how the drug class is already used clinically.

It is worth noting that TxGNN's rank #5453 prediction ("chronic lymphocytic leukemia/small lymphocytic lymphoma," L1, 34 trials including two completed Phase 3 RCTs — RESONATE/NCT01578707 and DUO/NCT02004522) is effectively re-predicting the drug's own established indication rather than a genuinely new one. We treat this as a positive sanity check on the model rather than a repurposing candidate. Similarly, the two top-ranked predictions (pregerminal-center and IGHV-mutated CLL/SLL molecular subtypes) are narrow biomarker-defined sub-populations of the same disease with zero trial or literature evidence (L5) and are not actionable. Follicular lymphoma is therefore the strongest genuine repurposing signal in this pack: mechanistically coherent, biologically adjacent to the original indication, and — unlike the CLL/SLL entry — actually represents a distinct disease.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01077518	Phase 3	Terminated	346	Randomized ofatumumab + bendamustine vs. bendamustine alone in indolent B-cell NHL (incl. FL) refractory to rituximab; largest FL-relevant RCT in the pack but stopped before completion
NCT01286272	Phase 2	Completed	135	Randomized ofatumumab + bendamustine ± bortezomib in untreated follicular lymphoma
NCT00394836	Phase 2	Completed	116	Single-arm, international trial of ofatumumab in rituximab-refractory FL
NCT02710643	Phase 2	Completed	110	Stage I/II FL treated with radiotherapy with/without ofatumumab, stratified by molecular (Bcl-2) status
NCT00494780	Phase 2	Completed	59	Randomized two-dose ofatumumab + CHOP in previously untreated FL
NCT01190449	Phase 2	Completed	51	CALGB trial of ofatumumab in previously untreated Stage II–IV follicular NHL
NCT01294579	Phase 2	Completed	49	Ofatumumab + bendamustine, then ofatumumab maintenance, in indolent B-NHL (incl. FL) relapsed after rituximab
NCT01239394	Phase 2	Completed	43	Ofatumumab as initial systemic treatment for indolent B-cell lymphoma (includes FL)
NCT00742144	Phase 1	Completed	6	Japanese safety/PK study of ofatumumab monotherapy in FL and CLL patients

Additional Phase 2 trials (e.g., NCT01263418, NCT00092274, NCT01119794, NCT01397591) were withdrawn or terminated with minimal/no enrollment and are omitted from this table as low-information.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31174236	2019	RCT	Cancer	CALGB 50904 (Alliance): randomized Phase 2 comparing ofatumumab+bendamustine vs. triplet with bortezomib in untreated high-risk FL
38937025	2024	Cohort (Phase 2)	The Lancet Haematology	FIL MIRO final results: MRD-driven radiotherapy ± ofatumumab in early-stage FL
30723894	2019	Phase 2 (single-arm)	British Journal of Haematology	CALGB 50901 (Alliance): single-agent ofatumumab in untreated, low/intermediate-risk FL
22409295	2012	Phase 1–2	British Journal of Haematology	Ofatumumab + CHOP (O-CHOP) as frontline therapy for FL; two dose levels compared
22389254	2012	Cohort	Blood	Ofatumumab monotherapy in rituximab-refractory FL; overall response rate 13%
24443277	2014	PK study	Journal of Clinical Pharmacology	Population PK of ofatumumab across CLL, FL, and rheumatoid arthritis populations
21083037	2010	Review	Expert Review of Hematology	Emerging therapeutic strategies in follicular lymphoma, including anti-CD20 agents
29934061	2018	Evidence review	Clinical Lymphoma, Myeloma & Leukemia	Evidence-based review of anti-CD20 antibody regimens across CLL, DLBCL, and FL
28983798	2017	Review	Advances in Therapy	20-year clinical experience with anti-CD20 therapy (rituximab) in B-cell malignancies, contextualizing ofatumumab's role
18390837	2008	Phase 1/2	Blood	First clinical use of ofatumumab in relapsed/refractory FL

Germany Market Information

Per the current regulatory dataset, ofatumumab has no active marketing authorization in Germany (total_licenses = 0, market_status = 未上市/Not Marketed, licenses = []). No product records are available to tabulate. This status should be verified directly against BfArM/EMA registries, since global regulatory history for this molecule is not captured by this dataset.

Cytotoxicity

Ofatumumab targets CD20-expressing B-cell malignancies and is used in the treatment of cancer (CLL/SLL, FL), meeting the antineoplastic criteria for this section.

Item	Content
Cytotoxicity Classification	Targeted therapy / Immunotherapy (anti-CD20 monoclonal antibody; CDC/ADCC-mediated B-cell depletion, not a conventional DNA-damaging cytotoxic agent)
Myelosuppression Risk	Not available in this evidence pack — please refer to the package insert warnings and precautions (neutropenia has been reported with anti-CD20 antibody class agents in general)
Emetogenicity Classification	Low (monoclonal antibodies typically carry minimal emetogenic potential; infusion-related reactions, rather than nausea/vomiting, are the predominant acute administration concern)
Monitoring Items	Complete blood count with differential; hepatitis B serology prior to therapy (anti-CD20 class carries reactivation risk); immunoglobulin levels; infusion-related reaction monitoring during administration
Handling Protection	Not classified as a conventional cytotoxic hazardous drug; standard biologic/monoclonal antibody infusion handling precautions apply rather than cytotoxic drug handling protocols — confirm against institutional policy

Safety Considerations

Please refer to the package insert for safety information. This evidence pack does not contain populated key warnings, contraindications, or drug interaction data for ofatumumab — this is flagged as a Blocking-severity data gap (DG001), meaning a formal safety pre-assessment (S1) cannot be completed until TFDA/package-insert warnings and contraindications are obtained.

Conclusion and Next Steps

Decision: Hold

Rationale: Follicular lymphoma has a mechanistically coherent, moderately well-supported evidence base (L2: 15 trials including a completed randomized Phase 2 and one terminated Phase 3, plus 20 publications), making it the most credible genuine repurposing signal in this pack. However, a Blocking-severity safety data gap (missing warnings/contraindications) prevents completion of the initial safety screening stage, and the drug currently holds no marketing authorization in Germany — both must be resolved before progressing beyond a research question.

To proceed, the following is needed:

TFDA/package-insert warnings and contraindications (resolves DG001, Blocking)
Confirmed mechanism of action and original-indication regulatory history from DrugBank (resolves DG002)
Drug-drug interaction data (currently not_found)
Direct confirmation of current marketing authorization status with BfArM/EMA
If advancing, prioritize completion or replication of a Phase 3 RCT specifically in FL, since current best evidence is Phase 2 (e.g., CALGB 50904) supplemented by one terminated Phase 3 trial (NCT01077518)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.